Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Roos

Showing results (331-340 of 608) with videos related to

Pageof 61
Sort By:
International Journal of Behavioral Medicine|July 13, 2002
Living with Huntington's disease: illness perceptions, coping mechanisms, and spouses' quality of lifeD I Helder, A A Kaptein, G M J Van Kempen, et al.
European Journal of Clinical Pharmacology|May 16, 2002
Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatmentD A M C van de Vijver, R A C Roos, P A F Jansen, et al.
British Journal of Health Psychology|March 5, 2003
Living with Huntington's disease: Illness perceptions, coping mechanisms, and patients' well-beingDesirée I. Helder, Ad A. Kaptein, Godfried M. J. Van Kempen, et al.
The Journal of Investigative Dermatology|August 22, 2000
13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptorsM Tsukada, M Schröder, T C Roos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 15, 2013
The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up studyKatia Youssov, Guillaume Dolbeau, Patrick Maison, et al.
Journal of Affective Disorders|November 29, 2011
Suicidality in Huntington's diseaseA A M Hubers, N Reedeker, E J Giltay, et al.
Psychosomatics|March 31, 2012
Psychiatric disorders in Huntington's disease: a 2-year follow-up studyW Reedeker, R C van der Mast, E J Giltay, et al.
Pharmacy World & Science : PWS|December 16, 2004
Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?David A M C van de Vijver, Raymund A C Roos, Paul A F Jansen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 30, 2013
Unified Huntington's disease rating scale for advanced patients: validation and follow-up studyKatia Youssov, Guillaume Dolbeau, Patrick Maison, et al.
BJU International|October 15, 2013
Treatment efficacy and outcomes using a third generation shockwave lithotripterAndreas Neisius, Jens Wöllner, Christian Thomas, et al.
Pageof 61

Showing results (331-340 of 608) with videos related to

Sort By:
Pageof 61
International Journal of Behavioral Medicine|July 13, 2002
Living with Huntington's disease: illness perceptions, coping mechanisms, and spouses' quality of lifeD I Helder, A A Kaptein, G M J Van Kempen, et al.
European Journal of Clinical Pharmacology|May 16, 2002
Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatmentD A M C van de Vijver, R A C Roos, P A F Jansen, et al.
British Journal of Health Psychology|March 5, 2003
Living with Huntington's disease: Illness perceptions, coping mechanisms, and patients' well-beingDesirée I. Helder, Ad A. Kaptein, Godfried M. J. Van Kempen, et al.
The Journal of Investigative Dermatology|August 22, 2000
13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptorsM Tsukada, M Schröder, T C Roos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 15, 2013
The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up studyKatia Youssov, Guillaume Dolbeau, Patrick Maison, et al.
Journal of Affective Disorders|November 29, 2011
Suicidality in Huntington's diseaseA A M Hubers, N Reedeker, E J Giltay, et al.
Psychosomatics|March 31, 2012
Psychiatric disorders in Huntington's disease: a 2-year follow-up studyW Reedeker, R C van der Mast, E J Giltay, et al.
Pharmacy World & Science : PWS|December 16, 2004
Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?David A M C van de Vijver, Raymund A C Roos, Paul A F Jansen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 30, 2013
Unified Huntington's disease rating scale for advanced patients: validation and follow-up studyKatia Youssov, Guillaume Dolbeau, Patrick Maison, et al.
BJU International|October 15, 2013
Treatment efficacy and outcomes using a third generation shockwave lithotripterAndreas Neisius, Jens Wöllner, Christian Thomas, et al.
Pageof 61